HCAT Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 -10.74%, SMA50 -20.4%, SMA200 -42.39%). The stock’s 14-day RSI is 35.22 (weak momentum), while the ATR of 0.14 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -65.62% below its high and over 4.79% above its low. Average 10-day trading volume of 538.68 thousand shares is below the 3-month average of 1.05 million, indicating normal recent market interest.

The stock is currently mid-range between its 52-week high and low $0.95 and $3.62. With a market capitalization of about $127.84 million, Health Catalyst, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.53). Key stats such as the average daily volume over the past year has been around 1.05 million shares, volume is running light vs its 52-week average. Headquartered in South Jordan, UT, Health Catalyst, Inc. operates in the Healthcare sector and the Medical - Healthcare Information Services industry. Led by CEO Benjamin Albert, the company employs approximately 1,200 people and listed since July 25, 2019. Health Catalyst, Inc. equips healthcare providers with crucial data and analytical technologies, alongside specialized services.

Health Catalyst, Inc. generated EPS of -$1.58 over the past year. Five-year average earnings growth is 38.24%. Wall Street analysts project EPS growth of 15.53% annually over the next five years. The latest quarter delivered EPS of $0.04. The next quarter is forecast at $0.09. Next year's EPS is expected at $23.35. Analyst sentiment is neutral. Analyst rating data shows there are 2 Strong Buy ratings, 2 Buy ratings, 13 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $5.00 to $1.00. The high target offers 189.02% upside. The low target suggests -42.2% downside. The mean target is $2.89. This offers 67.05% upside. Health Catalyst, Inc. earnings surprise history is a mixed track record. The quarter that ended August 06, 2026, missed forecasts by 33.87%. The prior quarter beat by 100.0%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in May 07, 2025.

Health Catalyst, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.94. This means the shares are trading below this model’s fair value.

Health Catalyst, Inc. has 73.89 million shares outstanding. The public float is 58.65 million shares, elevated short interest at 6.09% of float. This equals 3.65 million shares. The short ratio is 2.33 days. Institutional investors hold 82.28% of the float. Insiders own 5.48%. Burton Daniel D. holds 1.17 million shares, Hunt Bryan Truman has 238.67 thousand shares and Freeman Kevin Lee has 236.95 thousand shares.

Health Catalyst, Inc. trades at a P/E ratio of -0.47, slightly below the S&P 500 average, with a price-to-sales ratio of 0.44 and a price-to-book ratio of 1.26 suggesting the stock is closer to book value. The P/FCF stands at 9.76, also above market averages.

Our AI price prediction model suggests that Health Catalyst, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -13.29%, with price expected at $1.50 by September 24, 2026, within a range of $1.31 to $1.67 3-Month Outlook: Projected fall of -26.59%, reaching $1.27 by December 08, 2026, with a range of $1.14 to $1.38. 1-Year Outlook: Projected gain of 14.45%, with price at $1.98 by September 10, 2027, within a range of $0.00 to $0.00.

Health Catalyst, Inc. (NASDAQ:HCAT) shares are flat -7.53% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Health Catalyst, Inc. trading at a premium to the broader market with a P/E of -0.47. Analyst sentiment is mixed, with the majority of ratings in Hold territory and a mean price target of $14.72, suggesting 750.87% upside. Our AI forecast model points to short-term weakness (-13.29% over two weeks), a medium-term fall (-26.59% over three months), and a longer-term gain (14.45% over one year), with expected trading ranges indicating moderate volatility.